YBL-006은 독자기술로 개발한 PD-1 면역관문억제제로 임상시험을 진행중인 국내유일 PD-1 단일 항체입니다. 암세포의 표면에 있는 PD-L1, PD-L2 단백질이
면역세포인 T 세포 표면에 있는 PD-1 단백질과 결합하면 T 세포는 암세포를 제대로 인식할 수 없어
공격하지 못하지만 YBL-006은 T 세포의 PD-1에 달라붙어 암세포의 회피 기능을 억제합니다.

내용전달이 필요합니다.

LAG-3는 활성화된 T 세포 또는 조절 T 세포(regulatory T cell, Tregs) (CD4+ or CD8+)에 발현해 APC (antigen presenting cell) 나
암세포에 존재하는 리간드들인 MHC class II 혹은 LSECtin에 결합하여 T 세포의 활성을 억제함으로 암세포를 타겟 하는 면역세포의
항암 작용을 회피시키는데 관여합니다. YBL-011은 T 세포 표면의 LAG-3을 타겟 하여 APC 또는 암세포의 MHC class II 결합을
억제함으로써 T 세포의 활성을 높여 줌과 동시에 Treg 세포의 활성을 억제하여 암세포를 사멸하게 합니다.

YBL-013 is a bispecific T-cell engager in our proprietary ALiCE format that simultaneously targets PD-L1 on tumor cells and CD3 on T cells. By binding CD3, YBL-013 is capable of redirecting T cells to the tumor and activating the T cells primarily at the tumor site to kill cancer cells. By targeting PD-L1 it is also capable of functioning as an immune checkpoint inhibitor and suppressing an immune escape mechanism used by cancer cells.s

YBL-018은 와이바이오로직스가 개발한 Engager 플랫폼 형태를 가지고 있는 이중 항체입니다.
암세포의 표면에 있는 단백질인 B7-H3와 결합할 수 있는 항 B7-H3 재조합 단일사슬 부위와 T 세포의 표면에 있는 단백질인 CD3와
결합할 수 있는 항 CD3 재조합 단일사슬 부위로 이루어져 있으며, 암세포의 표적부위로 활성화된 T 세포를 끌어들여
T 세포에 의한 암세포의 사멸을 유도하는 기전을 가지고 있습니다.

YBL-001 is a Delta-like 1 homolog(DLK1)-targeting antibody-drug conjugate (DLK1-ADC) produced by conjugating an apoptotic payload to an antibody capable of being internalized and entering cells while binding specifically to DLK1 expressed in cancer cells. DLK1 has been observed to be overexpressed in patients with liver cancer, colorectal cancer, breast cancer, small cell lung cancer, and pancreatic islet cell tumors, and it is reported to be associated with cancer recurrence and metastasis as a cancer stem cell biomarker. YBL-001 can selectively kill DLK1-expressing cancer cells by specifically binding to DLK1, entering the cells, and releasing the conjugated toxic payload in the lysosome.

YBL-015 is an antibody-drug conjugate (ADC) produced by conjugating a cytotoxic payload to a B7-H3-specific antibody. B7-H3 is a promising and novel target of the immune checkpoint family. While the expression of B7-H3 in normal cells is very limited, it is highly expressed in patients with solid tumors in the breast, lung, pancreas, prostate, kidney, colon, skin or brain. YBL-015 utilizes a highly specific antibody for B7-H3 and can selectively kill cancer cells where B7-H3 is highly expressed.

YBL-003 is an immune checkpoint inhibitor being developed as a therapeutic antibody candidate for the treatment of solid tumors. It regulates the function of macrophages and activity of T cells to reactivate the immune system in the tumor microenvironment and kill cancer cells. Furthermore, the scope of the indications for YBL-003 can be expanded to include gastric cancer, lung cancer, breast cancer, and more, illustrating its high potential for use as an immuno-oncology agent targeting solid tumors.

내용전달이 필요합니다.

YBL-034 is a bispecific antibody targeting OX40L and TNF-a. It is used to treatment autoimmune diseases by inhibiting excessive T cell activation and the activity TNF-a, an inflammatory cytokine. This is an innovative pipeline that is expected to satisfy the unmet market need by addressing the low response rates of existing treatments.

AR087 is an immuno-oncology agent that activates immune cells and kills cancer cells by binding to a target antigen expressed on cancer cells. Y-Biologics plans to develop AR087 as a therapeutic agent for various solid tumors through a joint research collaboration with HK inno.N.